Landi D. Continuation of natalizumab versus interruption is associated with lower risk of relapses during pregnancy and postpartum in women with MS. Abstract 338. ECTRIMS 2019, 11-13 sept 2019, Stockholm, Zweden.
Dabrafenib plus trametinib bij BRAFV600E-gemuteerd laag- en hooggradig glioom
feb 2022 | Neuro-oncologie